, Tracking Stock Market Picks
Enter Symbol:
Allos Therapeutics, Inc. (ALTH) [hlAlert]

down 74.15 %

Allos Therapeutics, Inc. (ALTH) rated Overweight by JP Morgan

Posted on: Friday,  Jan 8, 2010  8:25 AM ET by JP Morgan

JP Morgan rated Overweight Allos Therapeutics, Inc. (NASDAQ: ALTH) on 01/08/2010, when the stock price was $7.12. Since
then, Allos Therapeutics, Inc. has lost 74.16% as of 09/05/2012's recent price of $1.84.
If you would have followed this JP Morgan's recommendation on ALTH, you would have lost 74.15% of your investment in 971 days.

Allos Therapeutics is a pharmaceutical company focused on developing andcommercializing innovative small molecule drugs, initially for improving cancer treatments. The company's lead product candidate is RSR13. RSR13 is a synthetic small molecule that increases the release of oxygen from hemoglobin, the oxygen-carrying protein contained within red blood cells.

JPMorgan is a leading financial services firm with one of the largest client franchises in the world. We partner with our clients to offer the most complete and innovative solutions in the industry to help them achieve their goals. For more than 200 years, we have taken a long-term approach to our clients and to the way we conduct business. Our firm has grown considerably in scale and scope, but our commitment to our core principle of doing "only first-class business... in a first-class way" has never been stronger.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/8/2010 8:25 AM Buy
as of 12/31/2010
1 Week down  -22.48 %
1 Month down  -10.83 %
3 Months down  -23.30 %
1 YTD down  -49.15 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy